CSIR-NCL and CPI (UK) Collaborate to Decarbonise Pharma Industry through 'Living Lab'
Revolutionizing the Pharma Industry
The CSIR-NCL and CPI (UK) are pioneering a collaborative effort through their new 'Living Lab', focusing on environmental sustainability within the pharmaceutical sector. This initiative aims to decarbonise processes, ultimately reducing carbon footprints associated with drug manufacturing.
Key Objectives of the Living Lab
- Enhance collaboration between UK and India for sustainable practices.
- Promote innovative technologies that facilitate decarbonisation.
- Respond to the growing demand for sustainable solutions in pharma.
Benefits for the Pharma Sector
The establishment of this 'Living Lab' in Pune is expected to lead to groundbreaking advancements in how pharmaceutical companies approach sustainability.
Implications for Global Pharma
This initiative not only positions India as a key player in global efforts to decarbonise but also sets a new standard for other nations to follow. By integrating innovative technologies and sustainable practices, CSIR-NCL and CPI (UK) aim to reshape the future of the pharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.